Get the Stockscreener App
8.07
1.82%
-0.15
After Hours:
8.73
0.66
+8.18%
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Zynex Inc stock is traded at $8.07, with a volume of 27,684.
It is down -1.82% in the last 24 hours and down -2.30% over the past month.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.
See More
Previous Close:
$8.22
Open:
$8.28
24h Volume:
27,684
Relative Volume:
0.31
Market Cap:
$256.99M
Revenue:
$193.67M
Net Income/Loss:
$4.82M
P/E Ratio:
17.54
EPS:
0.46
Net Cash Flow:
$15.53M
1W Performance:
-3.93%
1M Performance:
-2.30%
6M Performance:
-7.67%
1Y Performance:
-24.15%
1-Day Range:
$8.0206
$8.28
1-Week Range:
$8.02
$8.72
52-Week Range:
$7.15
$13.77
Zynex Inc Stock (ZYXI) Company Profile
Name
Zynex Inc
Sector
Industry
Phone
(800)-495-6670
Address
9655 MAROON CIRCLE, ENGLEWOOD, CO
Compare ZYXI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 9.30 | 0 | 0 | 0 | 0 | 0.00 | |
GOODO
Gladstone Commercial Corporation
|
20.79 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.1434 | 302.62M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
MOBBW
Mobilicom Limited Warrants
|
0.72 | 278.60M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
3.41 | 146.84M | 0 | 0 | 0 | 0.00 |
|
JUNE
Dhandho Junoon Etf
|
4.20 | 54.63M | 0 | 0 | 0 | 0.00 |
Zynex Inc Stock (ZYXI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-16-23 | Initiated | RBC Capital Mkts | Outperform |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Feb-28-22 | Reiterated | B. Riley Securities | Buy |
| Jul-16-21 | Upgrade | B. Riley Securities | Neutral → Buy |
| Mar-09-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Feb-26-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-29-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-28-21 | Downgrade | Northland Capital | Outperform → Market Perform |
| Sep-14-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Sep-09-20 | Upgrade | Northland Capital | Market Perform → Outperform |
| Jul-29-20 | Upgrade | B. Riley FBR | Neutral → Buy |
| Jul-20-20 | Initiated | Piper Sandler | Overweight |
| Jul-13-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-10-20 | Reiterated | H.C. Wainwright | Neutral |
| Jun-16-20 | Downgrade | Northland Capital | Outperform → Market Perform |
| May-19-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-01-20 | Initiated | Northland Capital | Outperform |
| Sep-23-19 | Initiated | H.C. Wainwright | Buy |
View All
Zynex Inc Stock (ZYXI) Latest News
Electrotherapy System Market Future Business Opportunities - openPR
How to Take Advantage of moves in (ZYXI) - Stock Traders Daily
Zynex partners with VA to expand pain management access By Investing.com - Investing.com Canada
Zynex partners with VA to expand pain management access - Investing.com
Zynex's SWOT analysis: pain management firm's stock faces growth hurdles By Investing.com - Investing.com Canada
Zynex's SWOT analysis: pain management firm's stock faces growth hurdles - Investing.com
Zynex partners with VA to offer pain management solutions for veterans - Proactive Investors
Zynex Announces Partnership To Conduct Business with Veterans Affairs (VA) Medical Centers, the Largest Healthcare Network in the United States (PR Newswire) - Aktiellt
Zynex partners with Veterans Affairs Medical Centers to deliver noninvasive pain relief solutions - Proactive financial news
Zynex, Inc. Sets Second Quarter 2023 Earnings Call - GuruFocus.com
Zynex CEO outlines plans for 2025 after revenue milestone – ICYMI - Proactive Investors Australia
Zynex Announces Completion of Its Laser Pulse Oximetry Trial - The Eastern Progress Online
Zynex UCSF Study Results Demonstrate Laser Technology Benefits in Resolving Racial Bias of Current LED Pulse Oximeters - The Malaysian Reserve
Zynex to Present at the HC Wainwright Global Investment Conference - The Eastern Progress Online
Zynex UCSF Study Results Demonstrate Laser Technology Benefits i - GuruFocus.com
Zynex study highlights precision of laser-based pulse oximeter in reducing racial bias - Proactive Investors UK
ZYXI Stock Gains on the Completion of NiCO's Clinical Verification Trial - MSN
Zynex Inc. (ZYXI) Tops Q3 Earnings Estimates - MSN
Zynex Sets Third Quarter 2024 Earnings Call - Longview News-Journal
Zynex Inc. Achieves $200M Milestone and Sets Ambitious Goals for 2025 - Proactive Investors UK
Non Invasive Pain Management Devices Market Overall Study - openPR
Objective long/short (ZYXI) Report - Stock Traders Daily
Zynex's (ZYXI) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
CHIEF FINANCIAL OFFICER Moorhead Daniel J was granted 5,000 shares and covered exercise/tax liability with 4,879 shares, decreasing direct ownership by 42% to 35,561 units (SEC Form 4) - Quantisnow
Zynex stock retains buy rating on FDA progress - Investing.com
Zynex stock retains buy rating on FDA progress By Investing.com - Investing.com Canada
Zynex completes clinical verification trial of pulse oximeter - Yahoo Finance
Muscle Stimulator Market Next Big Thing | Major Giants- Axiobionics, Zynex, NeuroMetrix - openPR
Hotchkis & Wiley Capital Management LLC Raises Holdings in Zynex, Inc. (NASDAQ:ZYXI) - MarketBeat
Zynex completes trial for new pulse oximeter technology By Investing.com - Investing.com Canada
Laser-Based Pulse Oximeter Advances Toward FDA Submission - Sleep Review
Zynex eyes FDA submission for NiCO pulse oximeter following successful verification trial - Proactive Investors Australia
Zynex completes trial for new pulse oximeter technology - Investing.com
Zynex Announces Open Oximetry Project Membership - GuruFocus.com
Zynex CFO Daniel Moorhead sells $80,800 in company stock By Investing.com - Investing.com Nigeria
Insider Sell Alert: Daniel Moorhead Sells 10,000 Shares of Zynex Inc (ZYXI) - GuruFocus.com
Zynex CFO Daniel Moorhead sells $80,800 in company stock - Investing.com
Zynex Inc Stock (ZYXI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Zynex Inc Stock (ZYXI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 14 '24 |
Sale |
8.09 |
2,000 |
16,180 |
14,603,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 12 '24 |
Sale |
9.24 |
2,000 |
18,480 |
14,607,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 07 '24 |
Sale |
9.17 |
2,000 |
18,340 |
14,613,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 11 '24 |
Sale |
9.09 |
2,000 |
18,180 |
14,609,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 08 '24 |
Sale |
8.77 |
2,000 |
17,540 |
14,611,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 13 '24 |
Sale |
8.37 |
2,000 |
16,740 |
14,605,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 06 '24 |
Sale |
8.82 |
2,000 |
17,640 |
14,615,662 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 04 '24 |
Sale |
8.67 |
2,000 |
17,340 |
14,619,350 |
| Sandgaard Thomas | PRESIDENT, CEO AND CHAIRMAN |
Nov 05 '24 |
Sale |
8.05 |
2,000 |
16,100 |
14,617,662 |
| MOORHEAD DANIEL J | CHIEF FINANCIAL OFFICER |
Nov 01 '24 |
Sale |
8.59 |
10,000 |
85,900 |
44,878 |
1.35%
4.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):